Please login to the form below

Not currently logged in
Email:
Password:

Keryx Biopharmaceuticals

This page shows the latest Keryx Biopharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Keryx Biopharmaceuticals' Fexeric approved in EU

Keryx Biopharmaceuticals' Fexeric approved in EU

Keryx Biopharmaceuticals' Fexeric approved in EU. New treatment option for chronic kidney disease. ... Keryx Biopharmaceuticals' Fexeric has been approved in Europe as a treatment for controlling phosphorus levels in adults with chronic kidney disease.

Latest news

  • Aeterna Zentaris under the cosh as myeloma candidate fails

    That result prompted the US developer of the drug, Keryx Biopharmaceuticals, to return rights to Aeterna Zentaris, which is also exploring the activity of perifosine in renal cell carcinoma, non-small

  • Extending the arsenal

    Introducing perifosine. Perifosine is a small-molecule compound that was originally discovered by Zentaris (now AEterna Zentaris) and has since been licensed to Keryx Biopharmaceuticals in the US, Canada and Mexico,

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics